BCL6-IN-7

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562071

CAS#: 2097518-46-0

Description: BCL6-IN-7 is a potent BCL6 protein-protein interaction inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

BCL6-IN-7 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562071
Name: BCL6-IN-7
CAS#: 2097518-46-0
Chemical Formula: C18H15ClN6O
Exact Mass: 366.0996
Molecular Weight: 366.8
Elemental Analysis: C, 58.94; H, 4.12; Cl, 9.66; N, 22.91; O, 4.36


Synonym: BCL6-IN-7; BCL6 IN 7; BCL6IN7; BCL6 inhibitor-7; BCL6 inhibitor 7; BCL6 inhibitor7;

IUPAC/Chemical Name: 5-((5-Chloro-2-((pyridin-3-ylmethyl)amino)pyrimidin-4-yl)amino)indolin-2-one

InChi Key: MUSYPBPUEKXCSS-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H15ClN6O/c19-14-10-22-18(21-9-11-2-1-5-20-8-11)25-17(14)23-13-3-4-15-12(6-13)7-16(26)24-15/h1-6,8,10H,7,9H2,(H,24,26)(H2,21,22,23,25)

SMILES Code: O=C1NC2=C(C=C(NC3=NC(NCC4=CC=CN=C4)=NC=C3Cl)C=C2)C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Kamada Y, Sakai N, Sogabe S, Ida K, Oki H, Sakamoto K, Lane W, Snell G, Iida M, Imaeda Y, Sakamoto J, Matsui J. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach. J Med Chem. 2017 May 25;60(10):4358-4368. doi: 10.1021/acs.jmedchem.7b00313. Epub 2017 May 11. PubMed PMID: 28471657.

2: Phadnis-Moghe AS, Li J, Crawford RB, Kaminski NE. SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 2016 Nov 1;310:41-50. doi: 10.1016/j.taap.2016.08.014. Epub 2016 Aug 18. PubMed PMID: 27546522; PubMed Central PMCID: PMC5064869.

3: Shaw LA, Bélanger S, Omilusik KD, Cho S, Scott-Browne JP, Nance JP, Goulding J, Lasorella A, Lu LF, Crotty S, Goldrath AW. Id2 reinforces TH1 differentiation and inhibits E2A to repress TFH differentiation. Nat Immunol. 2016 Jul;17(7):834-43. doi: 10.1038/ni.3461. Epub 2016 May 23. PubMed PMID: 27213691; PubMed Central PMCID: PMC4915968.

4: Dupont T, Yang SN, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. 2016 Jan 19;7(3):3520-32. doi: 10.18632/oncotarget.6513. PubMed PMID: 26657288; PubMed Central PMCID: PMC4823124.

5: Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 2015 Sep 1;365(2):190-200. doi: 10.1016/j.canlet.2015.05.029. Epub 2015 Jun 3. PubMed PMID: 26049022.

6: Cinar M, Rosenfelt F, Rokhsar S, Lopategui J, Pillai R, Cervania M, Pao A, Cinar B, Alkan S. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015 Jul;39(7):730-8. doi: 10.1016/j.leukres.2015.04.003. Epub 2015 Apr 17. PubMed PMID: 25916698.

7: Phadnis-Moghe AS, Crawford RB, Kaminski NE. Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6. Toxicol Sci. 2015 Mar;144(1):39-50. doi: 10.1093/toxsci/kfu257. Epub 2014 Dec 26. PubMed PMID: 25543051; PubMed Central PMCID: PMC4349138.

8: Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 2015 Feb 26;34(9):1073-82. doi: 10.1038/onc.2014.61. Epub 2014 Mar 24. PubMed PMID: 24662818; PubMed Central PMCID: PMC4175367.

9: Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature. 2014 Mar 27;507(7493):513-8. doi: 10.1038/nature12910. Epub 2014 Jan 19. PubMed PMID: 24463518; PubMed Central PMCID: PMC4012617.

10: Möröy T, Saba I, Kosan C. The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis-Binding Myc makes the difference. Semin Immunol. 2011 Oct;23(5):379-87. doi: 10.1016/j.smim.2011.09.001. Epub 2011 Oct 13. Review. PubMed PMID: 22000024.

11: Kim YS, Seo DW, Kong SK, Lee JH, Lee ES, Stetler-Stevenson M, Stetler-Stevenson WG. TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation. Cancer Lett. 2008 Sep 28;269(1):37-45. doi: 10.1016/j.canlet.2008.04.020. Epub 2008 May 23. PubMed PMID: 18502033; PubMed Central PMCID: PMC3448268.

12: Choi JW, An JS, Lee JH, Lee ES, Kim KH, Kim YS. Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. Mod Pathol. 2006 Jul;19(7):963-73. Epub 2006 Apr 28. PubMed PMID: 16648868.

13: Kanno T, Endo H, Takeuchi K, Morishita Y, Fukayama M, Mori S. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest. 2002 Jul;82(7):893-901. PubMed PMID: 12118091.

14: Shen HM, Michael N, Kim N, Storb U. The TATA binding protein, c-Myc and survivin genes are not somatically hypermutated, while Ig and BCL6 genes are hypermutated in human memory B cells. Int Immunol. 2000 Jul;12(7):1085-93. PubMed PMID: 10882420.

15: Bailey P, Downes M, Lau P, Harris J, Chen SL, Hamamori Y, Sartorelli V, Muscat GE. The nuclear receptor corepressor N-CoR regulates differentiation: N-CoR directly interacts with MyoD. Mol Endocrinol. 1999 Jul;13(7):1155-68. PubMed PMID: 10406466.